Boehringer/Pfizer Spiriva review
Executive Summary
Boehringer-Ingelheim/Pfizer's Spiriva (tiotropium) will be reviewed by FDA's Pulmonary-Allergy Drugs Advisory Committee Sept. 6. The NDA for the treatment of chronic obstructive pulmonary disease was submitted Dec. 13, 2001 (1"The Pink Sheet" Dec. 24, 2001, p. 18). The meeting will be at the Holiday Inn in Gaithersburg, Md., at 7:30 a.m. [To view a webcast/video broadcast of this meeting, visit FDAAdvisoryCommittee.com]...